"Ozempic body" is a set of search terms, not a finding. "Ozempic butt" alone is searched about 14,800 times a month in the United States, "Ozempic feet" about 9,900 and "Ozempic hands" about 2,900. None of them appears in a drug label or in a single medical paper. They are names people give to how a body can look after rapid, large weight loss: looser skin, a flatter seat, thinner limbs. The drugs have no known action on any of those places in particular.
What the trials did measure below the neck is more useful than the terms suggest: how much of the weight lost was fat and how much lean mass, how much came off the waist, and — in one small MRI study — what happened to fat and muscle in the thigh. This page sets that record out, then states what nobody has measured. It covers the body from the neck down; the face has its own page, Ozempic face. Everything was read on 20 October 2026; trial figures are averages, not predictions for anyone.
The terms, counted
| Phrase | US searches a month | Drug labels using it | PubMed records (title or abstract) |
|---|---|---|---|
| Ozempic butt | ~14,800 | 0 | 0 |
| Ozempic feet | ~9,900 | 0 | 0 |
| Ozempic hands | ~2,900 | 0 | 0 |
| Ozempic body | (head term) | 0 | 0 |
| Ozempic face, for comparison | — | 0 | 37 |
Search volumes: glp1ledger's keyword research, clickstream-corrected, October 2026. PubMed: exact-phrase [tiab] searches, 20 October 2026. Labels: the nine current US GLP-1 labels.
The face has a literature because surgeons and dermatologists treat it; the rest of the body has a search volume and no papers. That gap is the honest starting point: what people search for has not been studied under that name.
Where the weight comes from: fat and lean mass
The best whole-body measurement comes from DXA scans, the low-dose X-ray method that separates fat, lean tissue and bone.
Tirzepatide, SURMOUNT-1 substudy. 160 adults with scans at the start and at 72 weeks (124 on tirzepatide, 36 on placebo; mean starting weight 102.5 kg):
| Tirzepatide | Placebo | |
|---|---|---|
| Body weight | -21.3% | -5.3% |
| Fat mass | -33.9% | -8.2% |
| Lean mass | -10.9% | -2.6% |
| Share of loss that was fat | ~75% | ~75% |
Look M et al., Diabetes, Obesity and Metabolism 2025.
Two things follow. Fat fell three times as fast as weight did in proportional terms, so the body that results is leaner overall, not just smaller. And the fat-to-lean split was the same on drug as on placebo — about three parts fat to one part lean — which is the pattern of weight loss generally, not something peculiar to the drug. "Lean mass" on a DXA scan includes muscle, organs and water, so it is not the same as muscle; that distinction, and the drugs being developed to protect muscle, are on GLP-1 muscle loss.
The thigh, by MRI
The only regional measurement below the waist found for this page is an MRI substudy of STEP UP, the semaglutide 7.2 mg trial. 55 participants had valid scans (49 on semaglutide 7.2 or 2.4 mg, 6 on placebo). Against placebo, at 72 weeks:
| Compartment | Difference from placebo | Statistically significant? |
|---|---|---|
| Total adipose tissue | -11.1 litres | yes |
| Visceral (abdominal organ) fat | -1.5 litres | yes |
| Lean tissue | -1.7 litres | no |
| Thigh muscle volume | -1.1 litres | no |
| Fat infiltrating the thigh muscle | -0.92 percentage points | yes |
Hjelmesæth J et al., Diabetes, Obesity and Metabolism 2026 (secondary analysis of STEP UP).
The participants managed a mean of 13 sit-to-stand repetitions in 30 seconds at the start and 15 at week 72. The placebo group was six people, so the non-significant results mean "not shown", not "no change". The thigh is the nearest any trial has come to the regions the search terms name; the buttock, hands and feet have not been scanned in any trial found.
The waist
Waist circumference is measured in every major trial, and it is the body measurement the labels report:
| Trial | Drug | Waist change | Comparator |
|---|---|---|---|
| STEP 1, 68 weeks | Wegovy 2.4 mg | -13.5 cm | -4.1 cm (placebo) |
| STEP 3, 68 weeks, with intensive diet programme | Wegovy 2.4 mg | -14.6 cm | -6.3 cm (placebo) |
| SURMOUNT-5, 72 weeks | tirzepatide | -18.4 cm | -13.0 cm (semaglutide) |
| SELECT, 208 weeks | Wegovy 2.4 mg | -7.7 cm | -1.3 cm (placebo) |
Wegovy prescribing information (SPL 2026-06-18), Table 13; Aronne LJ et al., NEJM 2025; Ryan DH et al., Nature Medicine 2024.
Skin after large weight loss
No GLP-1 label lists loose or sagging skin, and no trial found for this page used skin laxity as an outcome. A PubMed search pairing semaglutide, tirzepatide or GLP-1 with "skin laxity", "loose skin", "skin sagging" or "excess skin" returned 33 records on 20 October 2026; the most recent are almost all about the face, and they are reviews and treatment frameworks rather than measurements.
What does exist is the surgical literature on people who have lost a great deal of weight and then have excess skin removed. The newest relevant study is from Aalborg University Hospital in Denmark: 282 adults who had body-contouring surgery between December 2022 and December 2025, grouped by how they had lost the weight. Compared with lifestyle-only loss, loss with a GLP-1 drug was associated with higher odds of post-operative infection (odds ratio 3.72) and of wound breakdown needing repair under general anaesthesia (odds ratio 16.71, with a very wide confidence interval of 1.99 to 139.88); prior bariatric surgery was not associated with more complications (Djebbara-Bozo et al., 2026). It is one centre's retrospective records, and it measures surgical outcomes, not how much skin the drugs leave behind. Whether GLP-1-driven weight loss leaves more loose skin than the same loss by diet or surgery has not been studied.
What has not been measured
- The buttocks, hands or feet as regions, by any method, in any GLP-1 trial found.
- Skin elasticity or laxity as a trial endpoint.
- Whether the speed of loss changes the result. It is often said that faster loss leaves more loose skin; no GLP-1 study has tested it.
- What happens after stopping. In the STEP 1 extension, people who stopped semaglutide regained 11.6 of the 17.3 percentage points they had lost within a year (Wegovy weight loss results); no study has followed what regain does to skin or regional fat.
The trial results for each brand are on Zepbound weight loss results and the Wegovy page above; before-and-after claims are examined on GLP-1 before and after. Changes in appearance during treatment, and any question about surgery afterwards, are for the person's prescriber or surgeon.
Sources
- Look M et al. "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight." Diabetes Obes Metab 2025;27:2720-2729, PubMed 39996356.
- Hjelmesæth J et al. "Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP." Diabetes Obes Metab 2026, PubMed 42764399.
- Djebbara-Bozo N et al. "GLP-1 receptor agonist use and postoperative complications after body contouring surgery following massive weight loss." J Plast Reconstr Aesthet Surg 2026;123:169-175, PubMed 42874170.
- Novo Nordisk, WEGOVY prescribing information, SPL effective 2026-06-18, DailyMed set ee06186f-2aa3-4990-a760-757579d8f77b, Table 13 — read 2026-10-20.
- Aronne LJ et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity." N Engl J Med 2025;393:26-36, PubMed 40353578.
- Ryan DH et al. "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial." Nat Med 2024;30:2049-2057, PubMed 38740993.
- Wilding JPH et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes Obes Metab 2022, PubMed 35441470.
- PubMed exact-phrase and keyword searches as written above, run 2026-10-20.